Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jamyia Clark"'
Publikováno v:
Journal of Cancer Therapy. 10:971-984
Introduction: Over the past few years, molecular targeted therapies have been emerging for the treatment of metastatic non-small cell lung cancer (NSCLC). Targeted therapy is associated with improved outcomes in patients with identified gene alterati
Publikováno v:
British journal of haematologyReferences. 192(4)
The experience of patients with mantle cell lymphoma (MCL) in community oncology practices, including reasons for treatment discontinuation, is sparse. This retrospective study sought to elucidate treatment patterns and outcomes of patients with MCL
Publikováno v:
Advances in therapy. 37(2)
Epidermal growth factor receptor (EGFR) mutations are observed in approximately 15% of patients with non-small cell lung cancer (NSCLC) in the USA. Little is known about treatment patterns in EGFR mutation-positive NSCLC following progression on or a
Autor:
Jamyia Clark, Kathleen M. Aguilar, Astra M. Liepa, William R. Schelman, A Scott Paulson, Lisa M. Hess, Zhanglin Lin Cui
Publikováno v:
Gastric Cancer. 21:831-844
Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer. This study was designed to describe ramucirumab monotherapy or combination therapy use in a community oncol
Autor:
Nicholas Liu, Kristina Yu-Isenberg, April Beeks, Jamyia Clark, Nicholas James Robert, Michelle A. Fanale, Christopher A. Yasenchak
Publikováno v:
Blood. 136:32-33
Introduction: Current National Comprehensive Cancer Network (NCCN) guidelines recommend one of three frontline (1L) regimens to treat stage III or IV classical Hodgkin Lymphoma (cHL): doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), brent
Autor:
Kathryn S. Kolibaba, John Brokars, Jie Zhou, Jamyia Clark, Brian Stwalley, Scott J Keating, Ronda Copher, Elias Jabbour, Arianna Kee
Publikováno v:
Blood. 136:36-37
Introduction:Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the unregulated proliferation of myeloid cells in the bone marrow and their accumulation in the blood. The approval of imatinib (IM) and second-generation T
Autor:
Lavanya Sudharshan, Arliene Ravelo, Keith L Dawson, Sheila Shapouri, Mitul Gandhi, Jamyia Clark
Publikováno v:
Blood. 134:5890-5890
Introduction: The 2017 US FDA approval of a subcutaneous (SC) injection form of rituximab made available an alternative means of administering rituximab for patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic ly
Autor:
Nicholas James Robert, Farrukh T. Awan, David Andorsky, Rebecca J. Chan, Jamyia Clark, Bianca Ruzicka
Publikováno v:
Blood. 134:2810-2810
Introduction: Idelalisib (IDELA, Zydelig®) is the first-in-class PI3Kδ inhibitor and is approved in the U.S. as an oral monotherapy for relapsed / refractory follicular lymphoma (R/R FL) after at least two prior lines of systemic therapy. IDELA's r
Autor:
Ancilla W. Fernandes, Melissa Pavilack, Eric Nadler, Jennifer Frytak, Jamyia Clark, Susan Amirian
Publikováno v:
Journal of Clinical Oncology. 36:9-9
9 Background: EGFR TKI therapy improves outcomes in pts with EGFRm+ NSCLC. NCCN guidelines recommend EGFRm testing for pts with NSCLC. Testing patterns and predictors of documented EGFRm testing were studied in a real-world setting. Methods: Adult pt
Autor:
Astra M. Liepa, Lisa M. Hess, Kat Aguilar, William R. Schelman, A. Paulson, Zhanglin Cui, Jamyia Clark
Publikováno v:
Annals of Oncology. 28:iii34